BREZTRI AEROSPHERE Market Summary

Key Factors Driving BREZTRI AEROSPHERE Growth

1. Strong efficacy in reducing COPD exacerbations and mortality

BREZTRI’s growth is strongly supported by the Phase III ETHOS trial, which demonstrated clinically meaningful reductions in COPD exacerbations compared with dual-combination therapies. AstraZeneca reported a 24% reduction in moderate or severe exacerbations versus Bevespi Aerosphere and a 13% reduction versus budesonide/formoterol dual therapy. Importantly, the study also showed a 46% reduction in all-cause mortality in a key secondary endpoint, significantly strengthening physician confidence in triple therapy for severe COPD management.

2. Rapid commercial uptake toward blockbuster status

BREZTRI has rapidly become one of AstraZeneca’s most important respiratory growth assets. Reuters reported that BREZTRI generated approximately US$978 million in 2024 sales, placing it close to blockbuster status despite relatively recent launch timing. AstraZeneca’s broader Respiratory & Immunology business grew 25% in FY2024, reflecting strong momentum across respiratory products including BREZTRI. The company continues guiding for high single-digit revenue growth in 2025, supported partly by respiratory franchise expansion.

3. Large and expanding global COPD burden

COPD remains one of the world’s largest chronic respiratory disease markets. AstraZeneca cited estimates showing approximately 391 million people globally live with COPD, while the disease remains a leading cause of hospitalization and mortality worldwide. Aging populations, smoking history, pollution exposure, and underdiagnosis in emerging markets continue expanding the addressable patient population for maintenance triple therapies such as BREZTRI.

4. Growing adoption of single-inhaler triple therapy

Treatment guidelines increasingly favor escalation to single-inhaler triple therapy for symptomatic COPD patients with exacerbation history. BREZTRI benefits from this structural treatment shift because it simplifies therapy compared with multiple-inhaler regimens, potentially improving adherence and reducing treatment complexity. AstraZeneca’s ATHENA clinical-development program involved more than 15,500 patients globally across 11 trials, helping establish a robust evidence base supporting triple-combination use.

5. Potential label expansion into asthma

A major future growth catalyst is BREZTRI’s potential expansion beyond COPD into asthma. In 2025, AstraZeneca announced that two late-stage asthma trials met all primary endpoints, demonstrating significant improvements in lung function among patients with uncontrolled asthma. Regulatory expansion into asthma could materially increase the drug’s long-term commercial opportunity and position BREZTRI more directly against blockbuster inhalers such as TRELEGY ELLIPTA.

BREZTRI AEROSPHERE Recent Developments

In April 2026, AstraZeneca's BREZTRI AEROSPHERE received FDA approval for asthma in adults and adolescents, marking the second FDA indication after its COPD approval. This came after the drug smashed the blockbuster sales threshold ($1 billion+ annually) in 2025, demonstrating strong commercial performance. The approval expands BREZTRI's market opportunity significantly by adding the larger asthma patient population to its existing COPD indication.

“BREZTRI AEROSPHERE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of BREZTRI AEROSPHERE for approved indication like Asthma and Chronic obstructive pulmonary disease in the 7MM. A detailed picture of BREZTRI AEROSPHERE’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the BREZTRI AEROSPHERE for approved indications. The BREZTRI AEROSPHERE market report provides insights about BREZTRI AEROSPHERE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current BREZTRI AEROSPHERE performance, future market assessments inclusive of the BREZTRI AEROSPHERE market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of BREZTRI AEROSPHERE sales forecasts, along with factors driving its market.

BREZTRI AEROSPHERE Drug Summary

BREZTRI AEROSPHERE is a triple-combination inhalation therapy developed by AstraZeneca for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug combines budesonide, an inhaled corticosteroid (ICS) that reduces airway inflammation, glycopyrrolate, a long-acting muscarinic antagonist (LAMA) that promotes bronchodilation by blocking muscarinic receptors, and formoterol fumarate, a long-acting beta2-agonist (LABA) that relaxes airway smooth muscle to improve airflow. Delivered via the Aerosphere pressurized metered-dose inhaler using co-suspension delivery technology, BREZTRI AEROSPHERE is designed to improve lung function, reduce exacerbation frequency, and enhance symptom control in patients with moderate-to-severe COPD. Clinical studies, including the ETHOS and KRONOS trials, demonstrated significant reductions in exacerbation risk, improvements in forced expiratory volume (FEV1), and better overall disease management compared with dual therapies, positioning BREZTRI AEROSPHERE as a leading fixed-dose triple therapy in COPD care. The report provides BREZTRI AEROSPHERE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the BREZTRI AEROSPHERE Market Report

The report provides insights into:

• A comprehensive product overview including the BREZTRI AEROSPHERE MoA, description, dosage and administration, research and development activities in approved indication like Asthma and Chronic obstructive pulmonary disease.
• Elaborated details on BREZTRI AEROSPHERE regulatory milestones and other development activities have been provided in BREZTRI AEROSPHERE market report.
• The report also highlights BREZTRI AEROSPHERE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The BREZTRI AEROSPHERE market report also covers the patents information, generic entry and impact on cost cut.
• The BREZTRI AEROSPHERE market report contains current and forecasted BREZTRI AEROSPHERE sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The BREZTRI AEROSPHERE market report also features the SWOT analysis with analyst views for BREZTRI AEROSPHERE in approved indications.

Methodology

The BREZTRI AEROSPHERE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BREZTRI AEROSPHERE Analytical Perspective by DelveInsight

• In-depth BREZTRI AEROSPHERE Market Assessment

This BREZTRI AEROSPHERE sales market forecast report provides a detailed market assessment of BREZTRI AEROSPHERE for approved indication like Asthma and Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted BREZTRI AEROSPHERE sales data uptil 2034.

• BREZTRI AEROSPHERE Clinical Assessment

The BREZTRI AEROSPHERE market report provides the clinical trials information of BREZTRI AEROSPHERE for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

BREZTRI AEROSPHERE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

BREZTRI AEROSPHERE Market Potential & Revenue Forecast

• Projected market size for the BREZTRI AEROSPHERE and its key indications
• Estimated BREZTRI AEROSPHERE sales potential (BREZTRI AEROSPHERE peak sales forecasts)
• BREZTRI AEROSPHERE Pricing strategies and reimbursement landscape

BREZTRI AEROSPHERE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• BREZTRI AEROSPHERE Market positioning compared to existing treatments
• BREZTRI AEROSPHERE Strengths & weaknesses relative to competitors

BREZTRI AEROSPHERE Regulatory & Commercial Milestones

• BREZTRI AEROSPHERE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

BREZTRI AEROSPHERE Clinical Differentiation

• BREZTRI AEROSPHERE Efficacy & safety advantages over existing drugs
• BREZTRI AEROSPHERE Unique selling points

BREZTRI AEROSPHERE Market Report Highlights

• In the coming years, the BREZTRI AEROSPHERE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The BREZTRI AEROSPHERE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BREZTRI AEROSPHERE’s dominance.
• Other emerging products for Asthma and Chronic obstructive pulmonary disease are expected to give tough market competition to BREZTRI AEROSPHERE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BREZTRI AEROSPHERE in approved indications.
• Analyse BREZTRI AEROSPHERE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted BREZTRI AEROSPHERE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of BREZTRI AEROSPHERE in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of BREZTRI AEROSPHERE? How strong is BREZTRI AEROSPHERE’s clinical and commercial performance?
• What is BREZTRI AEROSPHERE’s clinical trial status in each individual indications such as Asthma and Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BREZTRI AEROSPHERE Manufacturers?
• What are the key designations that have been granted to BREZTRI AEROSPHERE for approved indications? How are they going to impact BREZTRI AEROSPHERE’s penetration in various geographies?
• What is the current and forecasted BREZTRI AEROSPHERE market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of BREZTRI AEROSPHERE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BREZTRI AEROSPHERE for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is BREZTRI AEROSPHERE? What is the duration of therapy and what are the geographical variations in cost per patient?